Acrivon Therapeutics (ACRV) Cash from Investing Activities (2021 - 2026)

Acrivon Therapeutics (ACRV) has reported Cash from Investing Activities for 6 consecutive years, with $13.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 31.68% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at $60.0 million (up 256.26% YoY), while the FY2025 annual figure was $66.1 million, up 227.68% from the prior year.
• Cash from Investing Activities retreated to $13.1 million in Q1 2026 per ACRV's latest filing, from $21.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $21.5 million in Q4 2025 and bottomed at -$95.1 million in Q4 2022.
• Historically, Cash from Investing Activities has averaged -$3.7 million across 5 years, with a median of $9.3 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 69291.97% — and 2023, when it jumped 2347.47%.
• Acrivon Therapeutics' Cash from Investing Activities stood at -$95.1 million in 2022, then jumped by 121.6% to $20.5 million in 2023, then fell by 29.82% to $14.4 million in 2024, then surged by 49.35% to $21.5 million in 2025, then plunged by 39.01% to $13.1 million in 2026.
• Business Quant data shows ACRV's Cash from Investing Activities at $13.1 million in Q1 2026, $21.5 million in Q4 2025, and $5.9 million in Q3 2025.